The Claim

Ended federal funding for chemical and surgical gender procedures for minors through executive action and regulatory enforcement, driving the end to these harmful procedures for minors at health systems across the country.

The Claim, Unpacked

What is literally being asserted?

Three distinct claims: (1) the administration ended federal funding for gender-affirming care for minors, (2) this was accomplished through executive action and regulatory enforcement, and (3) the result was the end of these procedures at health systems across the country. The claim also embeds a medical judgment — that these procedures are “harmful” — as though it were a statement of settled fact.

What is being implied but not asserted?

The phrase “chemical and surgical gender procedures” implies that minors were routinely undergoing genital surgeries and being pumped full of hormones on a large scale — a picture of widespread, invasive medical intervention that the administration heroically stopped. The phrase “driving the end” implies the administration’s actions caused a nationwide cessation, as though these procedures no longer exist. The word “harmful” is presented as established medical consensus rather than a contested policy position that contradicts the stated views of the American Academy of Pediatrics, the American Medical Association, the Endocrine Society, and dozens of other medical organizations.

What is conspicuously absent?

The scale of what was being “ended.” Medicaid spent $31 million on all gender-affirming care services for enrollees under 18 in 2023 — 0.003% of all Medicaid spending. Only 85 gender-affirming surgeries were performed on minors annually in hospitals subject to the rule, and 96% of those were chest surgeries on patients aged 15-17, not genital procedures on young children. Also absent: the fact that a federal court issued a nationwide preliminary injunction blocking the core funding-withdrawal mechanism in March 2025, meaning the executive order has been substantially enjoined for most of the period in question. The claim credits “executive action” for hospital closures that were actually driven by DOJ investigation threats and proposed CMS rules from December 2025 — regulatory intimidation rather than lawful enforcement. Also absent: the administration’s own definition extends to individuals under 19, including legal adults, and the broader chilling effect on adult transgender care.

Evidence Assessment

Established Facts

Executive Order 14187, “Protecting Children from Chemical and Surgical Mutilation,” was signed January 28, 2025. ¹ The order directs federal agencies to stop funding, sponsoring, promoting, or supporting gender transition for individuals under 19. It defines “chemical and surgical mutilation” to encompass puberty blockers, sex hormones, and surgical procedures. It directed HHS to withdraw its March 2022 gender-affirming care guidance, rescind reliance on WPATH standards, publish a literature review within 90 days, and modify Medicare, Medicaid, and TRICARE coverage. It directed the DOJ to investigate potential False Claims Act violations by providers. The order’s definition of “children” includes 18-year-olds — legal adults in every U.S. state.

A nationwide preliminary injunction blocked the order’s core funding-withdrawal mechanism. ² On March 4, 2025, in PFLAG Inc. v. Trump (D. Md., No. 1:25-cv-00337), the court issued a nationwide preliminary injunction barring the federal government from conditioning or withholding funds from any healthcare entity for providing gender-affirming care to individuals under 19. The court found the order likely exceeded presidential authority, infringed on Congressional spending power, and facially discriminated based on sex and transgender status in violation of the Fifth Amendment. An earlier limited injunction from the Western District of Washington (February 28, 2025) had protected entities in four states. The government appealed to the Fourth Circuit, which held the case in abeyance pending the Supreme Court’s decision in United States v. Skrmetti.

The Supreme Court’s Skrmetti decision strengthened the administration’s legal position on state bans but did not directly resolve the federal funding question. ³ On June 18, 2025, in United States v. Skrmetti, the Supreme Court ruled 6-3 that Tennessee’s ban on gender-affirming care for minors did not require heightened equal protection scrutiny because the law’s exclusions were based on age and procedure rather than sex per se. The ruling upheld state bans in 25 states. However, the PFLAG v. Trump case raises distinct questions about presidential authority to condition federal funding, Congressional spending power, and statutory violations (Section 1557 of the ACA, the Rehabilitation Act) that Skrmetti did not address. The Fourth Circuit ordered rebriefing after Skrmetti but has not yet ruled.

Federal spending on gender-affirming care for minors was negligible relative to overall healthcare spending. ⁴ CMS’s own data shows Medicaid spent approximately $31 million on specified gender-affirming care services for enrollees aged 18 and under in 2023 — 0.003% of total Medicaid spending. Of this, 92% was non-surgical care (puberty blockers and hormones), and 66% occurred among those aged 15-18. The CBO estimated that removing federal funding for this care would save $700-$800 million over ten years, or roughly $70-$80 million per year. CMS Administrator Mehmet Oz estimated “at least” $250 million spent over 10 years by Medicare and Medicaid combined on this care for minors.

Gender-affirming surgery on minors was already rare and overwhelmingly limited to chest procedures on older teens. ⁵ A 2024 JAMA Network Open study found that in 2019, only 85 minors received gender-affirming surgery in the United States. The rate among those aged 15-17 was 2.1 per 100,000; for those aged 13-14, it was 0.1 per 100,000; and for those 12 and under, it was zero. Of minors who received surgery, 96.4% underwent chest-related procedures (mastectomy), not genital surgery. A separate analysis found that from 2016-2020, approximately 3,700 adolescents aged 12-18 underwent surgical interventions, of which over 3,200 were breast/chest surgery and roughly 400 were genital procedures. Less than 0.1% of U.S. adolescents received gender-affirming medications of any kind.

The administration escalated from executive order to investigation to proposed rulemaking over the course of 2025. ⁶ In April 2025, AG Pam Bondi issued an internal memo directing DOJ to investigate hospitals using the False Claims Act and other federal statutes. By July 2025, the DOJ had issued more than 20 subpoenas to doctors and clinics, demanding patient records including dates of birth, Social Security numbers, and medical histories. Three federal courts subsequently quashed these subpoenas, with a Massachusetts judge finding the subpoenas were issued “for an improper purpose — namely, to intimidate providers and patients.” In December 2025, CMS issued two proposed rules: one prohibiting Medicare/Medicaid-certified hospitals from providing gender-affirming care to minors as a condition of participation (regardless of payment source), and another barring Medicaid/CHIP reimbursement for these services. These proposed rules, still in the comment period, would affect an estimated 4,832 hospitals.

More than 40 hospitals have paused or ceased some form of gender-affirming care for minors since January 2025. ⁷ By February 2026, STAT News identified 42 hospitals or health systems that had paused or stopped some type of gender-affirming care for young people. Notable closures include Children’s Hospital Los Angeles (Center for Transyouth Health and Development, closed July 2025 after 30 years), Kaiser Permanente (paused surgeries for patients under 19, August 2025), Rady Children’s Health in San Diego (discontinued hormone therapy for under-19 patients, February 2026, affecting approximately 1,500 patients), Children’s Minnesota, Lurie Children’s in Chicago, and Children’s Hospital Colorado. Many cited the December 2025 CMS proposed rules and DOJ investigation referrals as the proximate cause. California AG Rob Bonta sued Rady Children’s Health for illegally terminating care. The Virginia AG directed at least two university hospital systems to cease providing care.

Major medical organizations continue to support evidence-based gender-affirming care for minors, though positions have become more nuanced on surgery. ⁸ The American Academy of Pediatrics called the December 2025 CMS rules a “baseless intrusion into the patient-physician relationship” and characterized the HHS report as misrepresenting medical consensus. The Endocrine Society reaffirmed its clinical guideline — based on 260+ studies — recommending no medical intervention before puberty, puberty blockers only from Tanner stage 2, hormones from age 16, and genital surgery only after age 18. In February 2026, the AMA updated its position to state that “surgical interventions in minors should be generally deferred to adulthood” due to insufficient evidence, while continuing to support non-surgical gender-affirming care. The American Society of Plastic Surgeons separately called for delaying gender-affirming surgery until age 19. Notably, the Endocrine Society’s existing guidelines already recommended against genital surgery before age 18 — the AMA’s “update” largely aligned with longstanding clinical practice rather than representing a dramatic reversal.

Strong Inferences

The real mechanism driving hospital compliance is economic coercion, not lawful regulatory enforcement. ⁹ The PFLAG injunction blocked the EO’s direct funding-withdrawal mechanism. The hospitals that subsequently stopped providing care cited not the executive order itself but the DOJ investigation threats (multiple subpoenas quashed by courts as improper), HHS Inspector General referrals, and the December 2025 CMS proposed rules — which remain proposals, not finalized regulations. The CMS conditions-of-participation rule would require hospitals to choose between providing gender-affirming care to even a single minor and participating in Medicare and Medicaid programs, which represent 44% of all hospital revenue. This is not regulatory enforcement in the traditional sense; it is leveraging the financial dependency of the entire hospital system on federal reimbursement to achieve a policy outcome that courts have thus far blocked through direct executive action.

The claim’s characterization of these procedures as “harmful” contradicts the weight of medical evidence, while acknowledging a genuine evidence debate. ¹⁰ The administration’s HHS report — authored primarily by individuals affiliated with organizations classified as anti-LGBTQ by the SPLC, including the Alliance Defending Freedom and the American College of Pediatricians (a small advocacy group distinct from the American Academy of Pediatrics) — was criticized by the AAP, AMA, Endocrine Society, and American Psychological Association for misrepresenting evidence. However, the international picture is genuinely more cautious than the U.S. medical establishment’s position circa 2020. The UK’s Cass Review (April 2024) recommended restricting puberty blockers to clinical trials and treating gender-distressed youth through holistic assessment rather than affirmation-only models. Sweden limited puberty blockers and hormones to research settings, finding that “the risks are likely to outweigh the expected benefits.” Finland restricted treatment to exceptional cases after thorough psychiatric evaluation. Denmark also sharply restricted access. These are not conservative political actions but evidence-based reassessments by public healthcare systems. The legitimate scientific debate about long-term outcomes, particularly for puberty blockers, is being exploited by the administration to justify a blanket prohibition rather than the individualized, cautious approach the Cass Review and Nordic countries actually recommended.

The order’s scope extends beyond minors into adult healthcare. ¹¹ By defining “children” as those under 19, the order restricts care for 18-year-olds who are legal adults in every state. The December 2025 CMS conditions-of-participation rule applies to all hospitals, creating pressure to stop providing care entirely rather than navigate complex compliance requirements. The House-passed “Big Beautiful Bill” initially expanded the Medicaid ban to adults of all ages in a midnight amendment, though this provision was ultimately removed by the Senate parliamentarian and dropped from the final bill. The chilling effect extends beyond the literal scope of the order: hospitals that closed their gender clinics typically stopped serving patients of all ages, not just minors. Children’s Hospital Los Angeles closed its 30-year-old Center for Transyouth Health and Development entirely.

What the Evidence Shows

The factual core of the claim is substantially accurate: the administration did take executive action targeting federal funding for gender-affirming care for minors, and health systems across the country have indeed stopped providing such care. To that extent, the claim describes real policy actions with real consequences. The steel-man case is also legitimate — there is a genuine international debate about the evidence base for pediatric gender-affirming care, particularly puberty blockers, and reasonable people can disagree about the appropriate standard of evidence required before providing irreversible medical interventions to minors.

But the claim’s framing is misleading in several important ways. First, the characterization of “chemical and surgical gender procedures” conjures images of invasive surgeries on young children. The reality: 96% of the rare surgeries performed on minors were chest procedures on 16- and 17-year-olds, zero surgeries were performed on children 12 or younger, and less than 0.1% of U.S. adolescents received gender-affirming medications of any kind. The vast majority of pediatric gender-affirming care is psychotherapy and, for older teens, puberty blockers or hormones — precisely the care that major medical organizations, including those in more cautious countries, continue to support with appropriate safeguards.

Second, the claim presents the outcome as the product of lawful “executive action and regulatory enforcement.” In reality, the executive order’s direct mechanism — withholding federal funds — was blocked by a nationwide court injunction in March 2025 that remains in effect. The hospital closures were driven not by lawful enforcement but by a campaign of investigatory intimidation: DOJ subpoenas (three of which were quashed by courts as improper), HHS Inspector General referrals, and proposed CMS rules that threaten to strip hospitals of all Medicare and Medicaid participation — 44% of their revenue — if they provide even one minor with a puberty blocker. When three federal judges independently conclude that the government’s own investigatory actions were designed to intimidate rather than investigate, the word “enforcement” deserves scrutiny.

Third, the claim declares these procedures “harmful” as settled fact. The overwhelming majority of major medical organizations disagree. The international reassessment in the UK and Nordic countries — which the administration frequently cites — recommended greater caution, individualized assessment, and research-setting protocols. None of them recommended blanket prohibition. The Cass Review explicitly warned against politicizing the evidence, and the Nordic countries’ approach is one of “ongoing reassessment,” not prohibition. The administration has taken the legitimate caution of the Cass Review and weaponized it into a maximalist policy that goes far beyond what even the most cautious international bodies recommend.

The Bottom Line

The claim is true in its factual core but misleading in its framing, its embedded medical judgment, and its characterization of the mechanism. The administration did sign an executive order (EO 14187) targeting federal funding for gender-affirming care for individuals under 19. Health systems have stopped providing care — more than 40 by February 2026. These are real policy outcomes.

But the claim elides critical context. The executive order’s direct funding-withdrawal mechanism has been blocked by a nationwide injunction since March 2025. The hospital closures were driven by a pressure campaign — DOJ subpoenas (repeatedly quashed by courts), IG referrals, and proposed CMS rules threatening total decertification — not by lawful regulatory enforcement as conventionally understood. The procedures being “ended” were already rare: 85 surgeries per year on minors nationally, almost all chest procedures on older teens, zero on children under 12. Medicaid spending on all gender-affirming care for minors was $31 million in 2023 — 0.003% of Medicaid spending. The claim that these procedures are “harmful” contradicts the stated positions of the AAP, AMA, and Endocrine Society, and goes far beyond what even cautious international reviews recommend. And the order’s definition of “children” as those under 19 extends restrictions to legal adults, while the broader campaign has chilled access for patients of all ages. What the claim presents as protecting children from harm, the evidence shows to be a maximalist culture-war intervention that overrides medical judgment through economic coercion, dressed up in the language of child safety.

Footnotes

1. Executive Order 14187, “Protecting Children from Chemical and Surgical Mutilation,” January 28, 2025. https://www.whitehouse.gov/presidential-actions/2025/01/protecting-children-from-chemical-and-surgical-mutilation/ ; Federal Register, 90 FR 8771 (February 3, 2025). https://www.federalregister.gov/documents/2025/02/03/2025-02194/protecting-children-from-chemical-and-surgical-mutilation ↩

2. PFLAG Inc. v. Trump, No. 1:25-cv-00337 (D. Md.), Preliminary Injunction granted March 4, 2025. Civil Rights Litigation Clearinghouse case tracker. https://clearinghouse.net/case/46028/ ; ACLU, “Federal Judge Blocks Trump Order Targeting Medical Care for Transgender Youth.” https://www.aclu.org/press-releases/federal-judge-blocks-trump-order-targeting-medical-care-for-transgender-youth ; Winston & Strawn, “Current Status of White House Executive Order on Gender-Affirming Care.” https://www.winston.com/en/insights-news/current-status-of-white-house-executive-order-on-gender-affirming-care ↩

3. United States v. Skrmetti, No. 23-477, decided June 18, 2025. https://www.supremecourt.gov/opinions/24pdf/23-477_2cp3.pdf ; KFF, “What Are the Implications of the Skrmetti Ruling for Minors’ Access to Gender Affirming Care?” https://www.kff.org/lgbtq/what-are-the-implications-of-the-skrmetti-ruling-for-minors-access-to-gender-affirming-care/ ↩

4. KFF, “New Trump Administration Proposals Would Further Limit Gender Affirming Care for Young People by Restricting Providers and Reducing Coverage.” https://www.kff.org/lgbtq/new-trump-administration-proposals-would-further-limit-gender-affirming-care-for-young-people-by-restricting-providers-and-reducing-coverage/ ; CMS proposed rule, Federal Register 2025-23464. https://www.federalregister.gov/documents/2025/12/19/2025-23464/medicaid-program-prohibition-on-federal-medicaid-and-childrens-health-insurance-program-funding-for ↩

5. Wright et al., “Prevalence of Gender-Affirming Surgical Procedures Among Minors and Adults in the US,” JAMA Network Open, June 27, 2024. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2820437 ; Harvard T.H. Chan School of Public Health, “Gender-affirming surgeries rarely performed on transgender youth.” https://hsph.harvard.edu/news/gender-affirming-surgeries-rarely-performed-on-transgender-youth/ ↩

6. Faegre Drinker, “Three District Courts Quash DOJ Subpoenas Investigating Gender-Affirming Care,” January 2026. https://www.faegredrinker.com/en/insights/publications/2026/1/three-district-courts-quash-doj-subpoenas-investigating-gender-affirming-care ; CMS proposed rule, Federal Register 2025-23465. https://www.federalregister.gov/documents/2025/12/19/2025-23465/medicare-and-medicaid-programs-hospital-condition-of-participation-prohibiting-sex-rejecting ; HHS, “HHS Acts to Bar Hospitals from Performing Sex-Rejecting Procedures on Children.” https://www.hhs.gov/press-room/hhs-acts-bar-hospitals-performing-sex-rejecting-procedures-children.html ↩

7. STAT News, “Amid federal pressure, more hospitals stop gender-affirming care for minors,” February 5, 2026. https://www.statnews.com/2026/02/05/hospitals-stop-gender-care-minors-trump-administration-pressure/ ; NPR, “California’s largest children’s hospital system ends gender-affirming care for youth,” February 6, 2026. https://www.npr.org/2026/02/06/nx-s1-5694689/californias-largest-childrens-hospital-system-ends-gender-affirming-care-for-youth ↩

8. AAP News, “AAP speaks out against HHS report on gender dysphoria.” https://publications.aap.org/aapnews/news/32145/AAP-speaks-out-against-HHS-report-on-gender ; STAT News, “Did the AMA change its position on surgery for transgender minors?” February 10, 2026. https://www.statnews.com/2026/02/10/medical-societies-trans-care-minors-ama-asps/ ; Endocrine Society, “Statement in Support of Gender-Affirming Care.” https://www.endocrine.org/news-and-advocacy/news-room/2024/statement-in-support-of-gender-affirming-care ↩

9. KFF, “President Trump’s Executive Order on Gender Affirming Care: Responses by Providers, States, and Litigation.” https://www.kff.org/other-health/president-trumps-executive-order-on-gender-affirming-care-responses-by-providers-states-and-litigation/ ; CMS proposed rule, Federal Register 2025-23465. https://www.federalregister.gov/documents/2025/12/19/2025-23465/medicare-and-medicaid-programs-hospital-condition-of-participation-prohibiting-sex-rejecting ↩

10. KFF, “Examining HHS Report on Pediatric Gender Dysphoria and Gender Conversion Efforts.” https://www.kff.org/lgbtq/u-s-department-of-health-and-human-services-report-on-pediatric-gender-dysphoria-and-gender-conversion-efforts/ ; Cass Review Final Report, April 2024 (summarized in Wikipedia). https://en.wikipedia.org/wiki/Cass_Review ; White House, “Report to the President on Protecting Children from Surgical and Chemical Mutilation Executive Summary.” https://www.whitehouse.gov/fact-sheets/2025/04/report-to-the-president-on-protecting-children-from-surgical-and-chemical-mutilation-executive-summary/ ↩

11. Williams Institute, “Impact of Ban on Gender-Affirming Care on Transgender Minors.” https://williamsinstitute.law.ucla.edu/publications/impact-gac-ban-eo/ ; The Intercept, “Republicans Launch Midnight Attack on Health Care Access for Trans Americans,” May 22, 2025. https://theintercept.com/2025/05/22/big-beautiful-bill-trans-medicaid-healthcare-minors-adults/ ; NPR, “California’s largest children’s hospital system ends gender-affirming care for youth,” February 6, 2026. https://www.npr.org/2026/02/06/nx-s1-5694689/californias-largest-childrens-hospital-system-ends-gender-affirming-care-for-youth ↩